<DOC>
	<DOCNO>NCT00460928</DOCNO>
	<brief_summary>Neonatal lupus ( NL ) name give group condition affect baby mother certain autoantibody component body 's cell call SSA/Ro SSB/La . NL appear temporary rash usually go away time baby 6 month old , rarely abnormal blood liver condition also improve time - cause permanent often life-threatening damage fetal heart , know congenital heart block ( CHB ) . In woman anti-Ro/La antibody pregnant first time , 2 % baby develop CHB . But woman already child CHB NL rash , risk CHB next pregnancy nearly 20 % . Unfortunately , complete ( third degree ) heart block unequivocally identify fetus , never reverse therapy try date . Our previous study strongly indicate scar conduction system ( heart 's natural `` pacemaker '' ) , consequence inflammation trigger mother 's antibody , damage even destroy cell allow heart beat normal rhythm . Instead , damage heart beat extremely slowly , extent fatal nearly 20 % affected baby ( death occur fetal demise ) . Nearly survive child CHB require permanent implantation pacemaker device . Because difficult treat repair damage heart , high-priority strategy try prevent inflammatory process irreversible scar occur . The aim clinical-based proposal determine whether treat pregnant mother intravenous immune globulin ( IVIG ) prevent development CHB .</brief_summary>
	<brief_title>Preventive IVIG Therapy Congenital Heart Block</brief_title>
	<detailed_description>Perhaps strong clinical association autoantibody SSA/Ro-SSB/La development congenital heart block ( CHB ) offspring , alarm prospect face 2 % primigravid mother antibody . Recurrence rate approach 20 % . Disease progress rapidly , advance block life-threatening cardiomyopathy observe less 2 week normal sinus rhythm . Once 3rd degree ( complete ) block identify , reversal never achieve , despite dexamethasone . This make biologic sense since signature lesion fibrosis atrioventricular node . Thus , strategy aim prevent disease assume high priority . Although disease expression fetus require additional factor amplify cascade fibrosis , maternal anti-Ro/La antibody necessary . Accordingly , eliminate fetal exposure antibody sound important approach . Intravenous immune globulin ( IVIG ) particularly exciting potential low maternal antibody level ( accomplished glucocorticoid immunosuppression ) , actually influence effector mechanism fetus . Aim 1 clinical trial ass efficacy IVIG prevent CHB . Proof efficacy challenge since CHB occur 2 % first pregnancies anti-Ro/La+ woman . However , give 10-fold high risk CHB pregnancy birth child neonatal lupus ( NL ) , mother previous NL-affected child target population study . Sample size calculation employ Simon 's 2-stage optimal design . Based 2-sided significance level 0.05 , power 90 % show reduction risk 5 % give prediction 18 % untreated subject get degree CHB , Stage 1 enroll 19 woman previous child CHB NL rash , receive IVIG ( 400 mg/kg IVIG every 3 week total 5 treatment ) week 12 24 gestation . If few 3 mother child 2nd 3rd degree block , additional 35 mother enrol Stage 2 ( total = 54 subject ) . IVIG consider efficacious worthy study fewer 6 54 subject child advanced CHB . Secondary outcome include 1st degree block , myocardial injury absent conduction defect , isolate endocardial fibroelastosis assess serial fetal echocardiogram EKG birth . Aim 2 address : ) effect IVIG antibody titer subclass ; b ) genetic polymorphism Fc gamma receptor ( FcgR ) platelet-activating factor acetylhydrolase potential association response IVIG ; c ) whether decrease anti-La antibody positively correlate level anti-La antiidiotypic antibody ; ) whether IVIG block expression activation marker human macrophage challenge opsonize apoptotic cardiocytes whether positively correlate increase expression inhibitory Fc receptor , FcgRIIb . In sum , IVIG promise agent may effect several level pathologic cascade antibody-mediated CHB .</detailed_description>
	<mesh_term>Heart Block</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Mother must currently intrauterine pregnancy less 12 week . Mother must antibodies SSA/Ro and/or SSB/La ( confirm clinical immunology laboratory Principal Investigator 's institution , NYUHospital Joint Diseases ) . Mother asymptomatic rheumatic disease ( lupus , Sjogren syndrome ) . Mother must previous child one following : ( ) congenital heart block ( degree ) document EKG live birth and/or echocardiogram fetal demise ; ( b ) characteristic neonatal lupus rash confirm photograph revealing annular lesion ( evaluate PI ) , dermatology note , and/or biopsy ; ( c ) congenital heart block rash . Mother may take 20 mg prednisone per day less . Mother antibodies either SSA/Ro SSB/La . Mother take great 20 mg prednisone per day . Mother condition would contraindicate use IVIG : ( ) prior serious reaction IVIG infusion ; ( b ) know IgA deficiency ; ( c ) intolerance volume load , e.g. , congestive heart failure ; ( ) nephrotic syndrome . Identification fetus follow structural lesion consider causal congenital heart block : ( ) atrioventricular septal defect ; ( b ) single ventricle ; ( c ) developmental tricuspid valve disease ; ( ) Ltransposition great artery ; ( e ) heterotaxia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>congenital heart block</keyword>
	<keyword>neonatal lupus</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>Sjogren syndrome</keyword>
	<keyword>autoantibody</keyword>
	<keyword>SSA/Ro</keyword>
	<keyword>SSB/La</keyword>
	<keyword>autoimmunity</keyword>
	<keyword>pregnancy</keyword>
	<keyword>intravenous immune globulin</keyword>
	<keyword>IVIG</keyword>
	<keyword>immunoglobulin</keyword>
</DOC>